Connect
MJA
MJA

    Severe symptomatic hypocalcaemia following a single dose of denosumab

    Jennifer M McLachlan, Gavin M Marx and Margaret Bridgman
    Med J Aust 2013; 199 (4): 242-243. || doi: 10.5694/mja13.10038
    Published online: 2 September 2013

    To the Editor: Denosumab, a receptor activator of nuclear factor κ-B (RANK) ligand inhibitor, is now considered first-line therapy to prevent skeletal-related events in patients with bone metastases secondary to breast cancer and castration-resistant prostate cancer.1,2

    • Jennifer M McLachlan
    • Gavin M Marx
    • Margaret Bridgman

    • Sydney Adventist Hospital, Sydney, NSW.

    Correspondence: jenny.clare@gmail.com
    Acknowledgements: 

    We thank the patient for allowing us to report this case.

    Competing interests:

    No relevant disclosures.

    Author
    remove_circle_outline Delete Author
    add_circle_outline Add Author
    Comment
    Do you have any competing interests to declare? *
    I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
    I/we agree to the Terms of use of the Medical Journal of Australia *
    Email me when people comment on this article
    Responses are now closed for this article.